Tags

Type your tag names separated by a space and hit enter

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Arch Neurol. 2002 Oct; 59(10):1541-50.AN

Abstract

BACKGROUND

Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression.

OBJECTIVE

To determine whether a range of dosages of coenzyme Q10 is safe and well tolerated and could slow the functional decline in PD.

DESIGN

Multicenter, randomized, parallel-group, placebo-controlled, double-blind, dosage-ranging trial.

SETTING

Academic movement disorders clinics.

PATIENTS

Eighty subjects with early PD who did not require treatment for their disability.

INTERVENTIONS

Random assignment to placebo or coenzyme Q10 at dosages of 300, 600, or 1200 mg/d.

MAIN OUTCOME MEASURE

The subjects underwent evaluation with the Unified Parkinson Disease Rating Scale (UPDRS) at the screening, baseline, and 1-, 4-, 8-, 12-, and 16-month visits. They were followed up for 16 months or until disability requiring treatment with levodopa had developed. The primary response variable was the change in the total score on the UPDRS from baseline to the last visit.

RESULTS

The adjusted mean total UPDRS changes were +11.99 for the placebo group, +8.81 for the 300-mg/d group, +10.82 for the 600-mg/d group, and +6.69 for the 1200-mg/d group. The P value for the primary analysis, a test for a linear trend between the dosage and the mean change in the total UPDRS score, was.09, which met our prespecified criteria for a positive trend for the trial. A prespecified, secondary analysis was the comparison of each treatment group with the placebo group, and the difference between the 1200-mg/d and placebo groups was significant (P =.04).

CONCLUSIONS

Coenzyme Q10 was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q10 than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.

Authors+Show Affiliations

Department of Neurosciences, Mail Code 0662, University of California-San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0662, USA. cshults@ucsd.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

12374491

Citation

Shults, Clifford W., et al. "Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline." Archives of Neurology, vol. 59, no. 10, 2002, pp. 1541-50.
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-50.
Shults, C. W., Oakes, D., Kieburtz, K., Beal, M. F., Haas, R., Plumb, S., Juncos, J. L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J. S., Reich, S., Stern, M., Watts, R. L., Kurlan, R., Molho, E., Harrison, M., & Lew, M. (2002). Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology, 59(10), 1541-50.
Shults CW, et al. Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline. Arch Neurol. 2002;59(10):1541-50. PubMed PMID: 12374491.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. AU - Shults,Clifford W, AU - Oakes,David, AU - Kieburtz,Karl, AU - Beal,M Flint, AU - Haas,Richard, AU - Plumb,Sandy, AU - Juncos,Jorge L, AU - Nutt,John, AU - Shoulson,Ira, AU - Carter,Julie, AU - Kompoliti,Katie, AU - Perlmutter,Joel S, AU - Reich,Stephen, AU - Stern,Matthew, AU - Watts,Ray L, AU - Kurlan,Roger, AU - Molho,Eric, AU - Harrison,Madaline, AU - Lew,Mark, AU - ,, PY - 2002/10/11/pubmed PY - 2002/10/31/medline PY - 2002/10/11/entrez SP - 1541 EP - 50 JF - Archives of neurology JO - Arch Neurol VL - 59 IS - 10 N2 - BACKGROUND: Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression. OBJECTIVE: To determine whether a range of dosages of coenzyme Q10 is safe and well tolerated and could slow the functional decline in PD. DESIGN: Multicenter, randomized, parallel-group, placebo-controlled, double-blind, dosage-ranging trial. SETTING: Academic movement disorders clinics. PATIENTS: Eighty subjects with early PD who did not require treatment for their disability. INTERVENTIONS: Random assignment to placebo or coenzyme Q10 at dosages of 300, 600, or 1200 mg/d. MAIN OUTCOME MEASURE: The subjects underwent evaluation with the Unified Parkinson Disease Rating Scale (UPDRS) at the screening, baseline, and 1-, 4-, 8-, 12-, and 16-month visits. They were followed up for 16 months or until disability requiring treatment with levodopa had developed. The primary response variable was the change in the total score on the UPDRS from baseline to the last visit. RESULTS: The adjusted mean total UPDRS changes were +11.99 for the placebo group, +8.81 for the 300-mg/d group, +10.82 for the 600-mg/d group, and +6.69 for the 1200-mg/d group. The P value for the primary analysis, a test for a linear trend between the dosage and the mean change in the total UPDRS score, was.09, which met our prespecified criteria for a positive trend for the trial. A prespecified, secondary analysis was the comparison of each treatment group with the placebo group, and the difference between the 1200-mg/d and placebo groups was significant (P =.04). CONCLUSIONS: Coenzyme Q10 was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q10 than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study. SN - 0003-9942 UR - https://www.unboundmedicine.com/medline/citation/12374491/Effects_of_coenzyme_Q10_in_early_Parkinson_disease:_evidence_of_slowing_of_the_functional_decline_ L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/vol/59/pg/1541 DB - PRIME DP - Unbound Medicine ER -